Four Senate Bills Signal Start Of 2005 Rx Importation Debate
This article was originally published in The Pink Sheet Daily
Executive Summary
Two partisan bills will compete with the reintroduction of the Dorgan/Snowe bill and the Pharmaceutical Market Access Act passed by the House in 2003. The Senate Health Committee plans to hold a hearing on the Dorgan/Snowe bill within 90 days.
You may also be interested in...
Postmarketing Trials, Not Discount Cards, Promote Drug Value, Harvard's Porter Says
Companies find themselves playing defense in debates on cost issues like reimportation because they have failed to demonstrate the value of their products, the Harvard Business School professor says. Merck's April announcement of a drug discount card program for the uninsured does not help promote value, Porter adds.
Postmarketing Trials, Not Discount Cards, Promote Drug Value, Harvard's Porter Says
Companies find themselves playing defense in debates on cost issues like reimportation because they have failed to demonstrate the value of their products, the Harvard Business School professor says. Merck's April announcement of a drug discount card program for the uninsured does not help promote value, Porter adds.
Former Commissioner Kessler To Testify At Senate Drug Import Hearing
The Health Committee will consider the Dorgan/Snowe importation bill (S 344) during the April 19 hearing. The witness roster includes no current FDA official or any other known critics of drug importation.